ConductScience.org, home

Paper9929751

Long-term safety of pravastatin-gemfibrozil therapy in mixed hyperlipidemia.

Iliadis EA and 1 other. Clin Cardiol, 1999. Cited by 35 papers, by iCite.

Cite this record

ConductScience Library. Long-term safety of pravastatin-gemfibrozil therapy in mixed hyperlipidemia. Papers, record 9929751. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/9929751

Download JSON
Sources
11 sources
Release
papers-2026-11-12-0.1.0

Paper

PubMed's record of the paper, with iCite's citation figures. No abstract is shown.

Title
Long-term safety of pravastatin-gemfibrozil therapy in mixed hyperlipidemia.
PubMed
Journal
Clin Cardiol
PubMed
Year
1999
PubMed
Publication types
Clinical Trial, Comparative Study, Journal Article
PubMed
Citations, by iCite
35
iCite
Relative citation ratio, by iCite
1.06
iCite
Revised in PubMed
2020-02-25
PubMed

Authors2

The authors in the order PubMed's record lists them, with the ORCID iDs it states.

OrderAuthorForenameKindORCID iD
1Iliadis EAE A
2Rosenson RSR S

Source PubMed

Download CSV of authors

Topics19

NLM's MeSH indexing of the paper, its major topics first.

MeSH termMajor
GemfibrozilMajor topic
Hydroxymethylglutaryl-CoA Reductase InhibitorsMajor topic
HyperlipidemiasMajor topic
PravastatinMajor topic
Cholesterol, HDL
Cholesterol, LDL
Creatine
Creatine Kinase
Drug Therapy, Combination
Female
Follow-Up Studies
Humans
Liver Function Tests
Male
Middle Aged
Retrospective Studies
Safety
Treatment Outcome
Triglycerides

Source PubMed

Download CSV of topics

References21

The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.

OrderPMIDTitleJournalYearIn PapersSource
11615846Gemfibrozil-lovastatin therapy for primary hyperlipoproteinemias.Am J Cardiol1992https://conductscience.org/library/papers/1615846PubMed
22006579Rhabdomyolysis associated with lovastatin and erythromycin use.West J Med1991https://conductscience.org/library/papers/2006579PubMed
32355431Myopathy and rhabdomyolysis associated with lovastatin-gemfibrozil combination therapy.JAMA1990https://conductscience.org/library/papers/2355431PubMed
43275892Rhabdomyolysis in patients receiving lovastatin after cardiac transplantation.N Engl J Med1988https://conductscience.org/library/papers/3275892PubMed
53290520Rhabdomyolysis and renal injury with lovastatin use. Report of two cases in cardiac transplant recipients.JAMA1988https://conductscience.org/library/papers/3290520PubMed
63421570Lovastatin, nicotinic acid, and rhabdomyolysis.Ann Intern Med1988https://conductscience.org/library/papers/3421570PubMed
74337382Estimation of the concentration of low-density lipoprotein cholesterol in plasma, without use of the preparative ultracentrifuge.Clin Chem1972https://conductscience.org/library/papers/4337382PubMed
87624744[Rhabdomyolysis in patients treated with simvastatin and cyclosporin: role of the hepatic cytochrome P450 enzyme system activity].Schweiz Med Wochenschr1995https://conductscience.org/library/papers/7624744PubMed
97637734Rhabdomyolysis from the coadministration of lovastatin and the antifungal agent itraconazole.N Engl J Med1995https://conductscience.org/library/papers/7637734PubMed
107663035Recent advances: the cytochrome P450 enzymes.Ann Pharmacother1995https://conductscience.org/library/papers/7663035PubMed
118059735Safety of combined pravastatin-gemfibrozil therapy.Am J Cardiol1994https://conductscience.org/library/papers/8059735PubMed
128420296Pravastatin and gemfibrozil alone and in combination for the treatment of hypercholesterolemia.Am J Med1993https://conductscience.org/library/papers/8420296PubMed
138498994Gemfibrozil-lovastatin-associated myalgia.Am J Cardiol1993https://conductscience.org/library/papers/8498994PubMed
148531308Efficacy and safety of a new HMG-CoA reductase inhibitor, atorvastatin, in patients with hypertriglyceridemia.JAMA1996https://conductscience.org/library/papers/8531308PubMed
158576954Differential sensitivity of C2-C12 striated muscle cells to lovastatin and pravastatin.J Mol Cell Cardiol1995https://conductscience.org/library/papers/8576954PubMed
168728350Effects of atorvastatin, an HMG-CoA reductase inhibitor, on hepatic oxidative metabolism of antipyrine.J Clin Pharmacol1996https://conductscience.org/library/papers/8728350PubMed
178737761In vitro comparative inhibition profiles of major human drug metabolising cytochrome P450 isozymes (CYP2C9, CYP2D6 and CYP3A4) by HMG-CoA reductase inhibitors.Eur J Clin Pharmacol1996https://conductscience.org/library/papers/8737761PubMed
188815751
Effect of combination therapy with lipid-reducing drugs in patients with coronary heart disease and "normal" cholesterol levels. A randomized, placebo-controlled trial. Harvard Atherosclerosis Reversibility Project (HARP) Study Group.
Ann Intern Med1996https://conductscience.org/library/papers/8815751PubMed
199002485Myositis and rhabdomyolysis associated with concurrent use of simvastatin and nefazodone.JAMA1997https://conductscience.org/library/papers/9002485PubMed
209172950Metabolism of cerivastatin by human liver microsomes in vitro. Characterization of primary metabolic pathways and of cytochrome P450 isozymes involved.Drug Metab Dispos1997https://conductscience.org/library/papers/9172950PubMed

See all 21 referencesDownload CSV of references

Cited by7

The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 35 citations.

PMIDTitleJournalYearIn PapersSource
19636324Myopathy with statin-fibrate combination therapy: clinical considerations.Nat Rev Endocrinol2009https://conductscience.org/library/papers/19636324PubMed
17410478Statin therapy depresses total body fat oxidation in the absence of genetic limitations to fat oxidation.J Inherit Metab Dis2007https://conductscience.org/library/papers/17410478PubMed
15485608Addressing cardiovascular risk beyond low-density lipoprotein cholesterol: the high-density lipoprotein cholesterol story.Curr Cardiol Rep2004https://conductscience.org/library/papers/15485608PubMed
12762976Combination lipid-lowering therapy in diabetes.Curr Diab Rep2003https://conductscience.org/library/papers/12762976PubMed
12150329Statins and the risk of rhabdomyolysis.J Endocrinol Invest2002https://conductscience.org/library/papers/12150329PubMed
11487448Combination lipid-altering therapy: an emerging treatment paradigm for the 21st century.Curr Atheroscler Rep2001https://conductscience.org/library/papers/11487448PubMed
10980849Combination drug therapy for combined hyperlipidemia.Curr Cardiol Rep1999https://conductscience.org/library/papers/10980849PubMed

Download CSV of cited by

Genes1

The genes the Gene search release ties to the paper: Swiss-Prot's references first, then PubTator's text mining.

GeneNCBI Gene IDLinked byIn Genes
CMPK151727PubTator's text mininghttps://conductscience.org/library/genes/51727

Source NCBI Gene

Download CSV of genes

Data dates

The date of each source this release read.

PubMed
2026-11-06
PubMed
iCite
2026-11-05
iCite
PMC's ID file
2026-11-05
PMC's ID file
NIH RePORTER's grant and paper links
2026-11-01
NIH RePORTER's grant and paper links
Trials
2026-11-12
Gene search
2026-11-11
Pipelines
2026-09-18

None in this release

  • Grants
  • Trials
  • Comments and corrections
  • Drugs
  • Data

Sources 11

  • ChEMBL, through Open TargetsCC BY-SA 3.0
  • ClinicalTrials.govNo license stated
  • HGNCCC0
  • iCiteCC BY 4.0
  • NCBI GenePublic domain (US government)
  • NIH RePORTER's grant and paper linksPublic domain
  • Open TargetsCC0 1.0
  • PMC's ID filePublic domain (US government)
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0
Each source's terms
  • ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • ClinicalTrials.govnone stated
  • HGNCCC0: https://www.genenames.org/about/license/
  • iCiteCC BY 4.0
  • NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
  • Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this paper from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/papers/v1/9929751

GET https://conductscience.org/api/papers/v1/9929751/references?page=2